Prescribing Semaglutide for Weight Loss in Non-Diabetic, Obese Patients is Associated with an Increased Risk of Erectile Dysfunction: A TriNetX Database Study
Importantly, large cardiovascular outcome trials consistently demonstrate benefit rather than harm
It can show up as a snacky feeling, so we go look in the cupboard or fridge for something to eat even though our brain is asking for water, Salamon says
Potential rebound: Abrupt discontinuation, even from low doses, may cause appetite rebound and metabolic slowdown
12 , 13 Therapeutically, glucagon-like peptide-1 receptor agonists (GLP-1) are employed to treat diabetes but they have also been approved as an adjunct to a lower calorie diet to reduce total body weight, and to enhance the metabolic profile readings for diabetic and non-diabetic patients
And during the 2023-2024 shortage, patients who rationed their supply discovered that spaced-out or reduced doses still provided some appetite suppression